Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07493512 · ClinicalTrials.gov registry record · Phase 1
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
A Phase 1 study, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT07493512 is a Phase 1 study that is actively recruiting participants, run by Amgen. The registered enrollment target is 40 participants.
The verdict
NCT07493512, a Phase 1 study, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The primary objective of this trial is to determine the safety profile of xaluritamig at the proposed regimen in adult participants with metastatic castration-resistant prostate cancer (mCRPC).
Interventions
- DRUG Xaluritamig
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-04-28 |
| Est. Completion | 2030-07-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07493512
The ClinicalTrials.gov registry entry for NCT07493512 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Xaluritamig is the first listed.
NCT07493512 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07493512 about?
NCT07493512 is a clinical study titled "Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer". The primary objective of this trial is to determine the safety profile of xaluritamig at the proposed regimen in adult participants with metastatic castration-resistant prostate cancer (mCRPC).
What is the current status of trial NCT07493512?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2026-04-28. Estimated completion is 2030-07-30.
What interventions are being tested in trial NCT07493512?
The interventions under investigation include: Xaluritamig (DRUG).
Who is sponsoring clinical trial NCT07493512?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.